Camp4 Therapeutics Corp. Enters and Terminates Agreements
Ticker: CAMP · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1736730
Sentiment: neutral
Topics: material-definitive-agreement, termination
TL;DR
Camp4 just signed and broke a deal. Details TBD.
AI Summary
On December 22, 2025, Camp4 Therapeutics Corp. entered into a material definitive agreement and terminated a material definitive agreement. The filing does not provide specific details on the nature of these agreements or any associated financial figures.
Why It Matters
This filing indicates significant corporate activity for Camp4 Therapeutics Corp., suggesting potential shifts in partnerships, collaborations, or strategic directions that could impact its future operations and value.
Risk Assessment
Risk Level: medium — The lack of specific details regarding the material definitive agreement and its termination creates uncertainty about the company's strategic direction and financial implications.
Key Players & Entities
- Camp4 Therapeutics Corp. (company) — Registrant
- December 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-42365 (commission_file_number) — SEC File Number
- One Kendall Square Building 1400 West, 3rd Floor (address) — Principal executive offices
- Cambridge, MA (location) — City and State of principal executive offices
- 617-651-8867 (phone_number) — Registrant's telephone number
FAQ
What was the nature of the material definitive agreement entered into by Camp4 Therapeutics Corp. on December 22, 2025?
The filing states that Camp4 Therapeutics Corp. entered into a material definitive agreement on December 22, 2025, but does not provide specific details about its nature.
What led to the termination of the material definitive agreement by Camp4 Therapeutics Corp.?
The filing indicates the termination of a material definitive agreement, but does not specify the reasons or circumstances for this termination.
Are there any financial implications or dollar amounts associated with the new agreement or the terminated agreement?
The provided text of the 8-K filing does not mention any specific dollar amounts or financial terms related to the agreements entered into or terminated.
Does the filing provide any context on the counterparty to the material definitive agreement?
No, the filing does not disclose the name of the other party involved in the material definitive agreement.
When was the report filed with the SEC?
The report was filed as of December 23, 2025.
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2025-12-23 16:59:17
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Market
- $40.00 — base rent under the Watertown Lease is $40.00 per rentable square foot, subject to an
- $85.00 — ar term at market rent of not less than $85.00 per rentable square foot. The Commencem
- $2.1 million — pay ARE 59 a fee totaling approximately $2.1 million (the "Lease Modification Fee"), to be p
Filing Documents
- camp-20251222.htm (8-K) — 27KB
- 0001736730-25-000116.txt ( ) — 150KB
- camp-20251222.xsd (EX-101.SCH) — 2KB
- camp-20251222_lab.xml (EX-101.LAB) — 24KB
- camp-20251222_pre.xml (EX-101.PRE) — 14KB
- camp-20251222_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 22, 2025 (the "Effective Date"), CAMP4 Therapeutics Corporation (the "Company") and ARE-MA Region No. 59, LLC ("ARE 59") entered into the First Amendment (the "Lease Amendment") to the Lease Agreement (the "Cambridge Lease"), dated October 3, 2019, by and between the Company and ARE 59. The term of the Cambridge Lease, which provides for approximately 30,760 square feet of laboratory and office space located at One Kendall Square, Cambridge, Massachusetts (the "Cambridge Premises"), was scheduled to expire on June 30, 2027. The Lease Amendment will accelerate the termination date of the Cambridge Lease to the date (the "Early Termination Date") thirty days after the Commencement Date of the Watertown Lease (as such terms are defined below). Base rent under the Cambridge Lease will be abated from October 1, 2025 through the Early Termination Date, provided no default occurs under either the Cambridge Lease or the Watertown Lease. Also on the Effective Date, the Company entered into a Lease Agreement (the "Watertown Lease") with ARE-MA Region No. 75, LLC ("ARE 75"), an affiliate of ARE 59, for approximately 44,000 rentable square feet of laboratory and office space located at 100 Talcott Avenue, Watertown, Massachusetts (the "Watertown Premises"). The Watertown Lease provides for an initial term commencing on the date that ARE 75 delivers the Watertown Premises to the Company (the "Commencement Date") and ending on June 30, 2030. The annual base rent under the Watertown Lease is $40.00 per rentable square foot, subject to annual increases of 3%. The Company may extend the Watertown Lease for an additional five-year term at market rent of not less than $85.00 per rentable square foot. The Commencement Date is targeted to occur 180 days after the Effective Date, and, subject to the Additional Base Rent Abatement Period (as defined below), the Company's obligation to pay base rent under the Watertown Le
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 1.02 of this Current Report on Form 8-K by reference.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: December 23, 2025